Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new investigational biologic is taking a two-for-one approach to fighting asthma. Lunsekimig, which blocks both TSLP and IL-13 inflammatory pathways, reduced asthma exacerbations by 55.3% at its highest dose compared to placebo in the phase II AIRCULES trial. Researchers say the results support a promising new frontier of multi-pathway targeting in asthma treatment.
A new investigational biologic is taking a two-for-one approach to fighting asthma — and the early results are turning heads. Lunsekimig, which simultaneously blocks both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), hit its primary endpoint in the phase II AIRCULES trial, cutting asthma exacerbations by 55.3% at the highest dose (300 mg every 28 days) versus placebo. Lung function improvements were rapid and sustained, patient-reported outcomes improved, and the drug was well tolerated across all doses — with no treatment-related deaths.
What makes lunsekimig stand out is its strategy of hitting both an upstream initiator and a downstream driver of airway inflammation simultaneously. Researchers noted especially strong responses in patients with more severe disease or high type 2 inflammation markers, and — notably — consistent responses regardless of eosinophil levels.
By the Numbers:
Why it matters: Most current asthma biologics target only one inflammatory pathway, leaving many patients as partial responders. Lunsekimig's dual-blockade approach could represent the next generation of asthma therapy — one that may eventually help patients achieve complete remission rather than just symptom control.
